Introduction: Patients with end-stage renal disease are burdened by a complex medication regimen, but little is known about the belief about medicine among dialysis-and renal transplant (RTX) patients. Patients' beliefs about medicines may influence drug adherence and thereby affect morbidity and mortality. The aim of the present study was to assess the beliefs about medicine in dialysis as well as after RTX.
INTRODUCTION
Patients with end-stage renal disease (ESRD) are often highly burdened by comorbid diseases and disturbing symptoms in addition to the treatment of the renal disease. Comprehensive treatment regimens including both lifestyle interventions and medications are often necessary. ESRD patients have the highest daily pill burden in patients with chronic diseases, with an average of 12-19 pills per day. [1] [2] [3] Adherence is important to alleviate disturbing symptoms, prevent graft rejection in renal transplanted patients (RTX) and to prolong survival. [4] [5] [6] However, adherence may be especially challenging in complicated treatment regimens with a heavy pill burden. 7 In a recent review of 44 studies which included 37,224 hemodialysis patients, nonadherence was observed in 12.5% to 98.5% of the population, 4 much higher than what has been found in patients with other chronic illnesses. [8] [9] [10] In the review, beliefs about medicines were found to be a possible barrier to adherence. Patients expressing negative beliefs about their medication were more likely to be nonadherent. Nonadherence has been found to be frequent also in recipients of solid organ transplants, ranging from 20% to 50%.
5 RTX patients demonstrated the highest level of nonadherence to immunosuppressive drugs compared to other solid organ recipients. 11 Nonadherence in this group may be related to side-effects of medications, patients' perception of the necessity and the perceived risk of drug dependency. 5, 12 There are few studies on beliefs about medicines among dialysis-and RTX patients, and to our knowledge there are no studies investigating how the beliefs about medicine may change in the transition from dialysis to transplantation. Thus, the object of the present study was to explore beliefs about medicines in patients in dialysis and in the transition from dialysis to after RTX.
MATERIALS AND METHODS
The inclusion process has been described previously, 13 but is delineated below. Between August 2005 and February 2007, 301 dialysis patients from 10 different hospitals in Norway, five of them university hospitals, were included in a cross-sectional study. All patients over 18 years of age receiving either hemodialysis (HD) or peritoneal dialysis (PD) for more than 2 months were invited to participate. Patients with cognitive dysfunction, a major psychiatric disorder or inadequate Norwegian language skills were not included. Hospitalized patients were not included, but could be enrolled 4 weeks or more after hospital discharge if they were clinically stable. Both oral and written information about the study was provided to the patients, and a signed consent was required before study inclusion. The patients answered the questionnaires during a regular HD session or during a scheduled visit for the PD patients. To ensure standardization, HD patients were given the questionnaires approximately 30 minutes into the dialysis session to avoid distractions during the start-up procedure, and they had to complete the questionnaires by the end of the dialysis session. PD patients answered the questionnaires after a scheduled outpatient visit and had to complete the questionnaires before leaving the hospital. Clinical information was obtained from patient records. Daily pill burden was calculated based on data from patient records. When exact number of tablets was not listed, the lowest possible tablet count based on type of medication and listed dosage was plotted. When listed as "with every meal," it was counted as three tablets. Medications given less than once daily were not counted.
In 2010-2012, the 110 patients who survived the follow-up period and subsequently had been transplanted were approached and invited to participate in a follow-up study. The same exclusion criteria applied for the followup part, and both oral and written consent was required before enrolment. The same questionnaires were answered after a scheduled visit to the outpatient clinic.
The Regional Committees for Medical and Health Research Ethics in Norway approved the study protocol, and concession to file patient information was obtained from the National Data Inspectorate. The study was conducted in accordance with the Helsinki Declaration.
The Beliefs about medicine questionnaire (BMQ) was distributed by mail to a representative sample of the general population by a professional company in 2004. The sample included 1000 persons over 18 years of age, of which 426 completed the questionnaire.
Study instruments
The Beliefs about Medicines Questionnaire was developed by Horne et al. 14 The BMQ consists of 18 items each answered on a 5-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, 5 = strongly agree) and further divided into two main categories, BMQ General and BMQ Specific. The general items are grouped into the subscales Harm and Overuse. The scores range from 4 to 20, with a midscale score of 12, where a higher score reflects that patients believe medications to be more harmful and overused. The specific part of the questionnaire is used to assess the patients' beliefs about the specific medications prescribed for their condition. The items are divided into the categories Concern and Necessity. The scores range from 5 to 25, with a midscale score of 15, and a higher score reflects more concern and a higher belief in their necessity, respectively. The subscales and their associated questions are presented in Table 2 .
A necessity-concern differential was calculated to identify if the patients believed the necessity of their medication outweigh the cost of taking it, as suggested by Horne and Weinman. 15 The differential score ranges from −20 to 20, with a positive number indicating that the respondents believe the benefit of medication to be higher than their concerns about taking them.
The Beck Depression Inventory was used to assess depressive symptoms. It is a self-report questionnaire consisting of 21 items, each scored on a scale from 0 to 3 and summarized into a total score ranging from 0 to 63. In dialysis patients, a score of ≥17 has been suggested as clinically significant for depression. 16 The Norwegian version of the questionnaire has been validated in different disease populations, including dialysis patients, and the validity and reliability of the instrument is good. 16, 17 The Charlson comorbidity index (CCI) 18 was used to assess comorbidity. It provides a weighted score for 17 predefined comorbid conditions: Coronary artery disease, heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disorder, peptic ulcer disease, mild to severe liver disease, diabetes with or without end-organ damage, hemiplegia, moderate to severe renal disease, tumors with or without metastases, leukemia, lymphoma, and AIDS. To be able to use CCI as an independent variable in regression models that included age, a CCI score without age was calculated.
Statistical analysis
Data are presented as mean AE standard deviation (SD) or median with interquartile range (IQR) if the data was skewed. Student-t test and Mann-Whitney U tests were used to compare two groups, the latter when data was skewed. To compare changes from dialysis to after RTX, the paired Wilcoxon rank test was used. To assess independent associations with BMQ, multiple linear regression models were built. Independent variables were chosen based on correlations (Spearman rho) between the BMQsubscales and clinical and demographic variables, with cut off set as P value <0.1. Education was scaled from 1 to 3 (1 = primary school, 2 = secondary school, and 3 = university). A significance level of P < 0.05 was chosen for all analyses. Preliminary analyses were conducted to ensure that the assumptions of normality, linearity, and multicollinearity were not violated. The statistics were analyzed using IBM SPSS statistics version 24/25.
RESULTS

Beliefs about medicine in dialysis
Of the 301 dialysis patients enrolled in the study, 272 patients completed the BMQ questionnaire, details given in Figure 1 . The patients had a median age of 62 (IQR 50-73) years, 66.1% were males and 80.7% were treated with HD. The average daily pill burden was 14 (IQR 10-18) pills per day (Table 1) .
In the BMQ General, the patients scored 10.2 AE 2.7 in the Harm subscale and 11.8 AE 2.9 in the Overuse subscale. In the BMQ Specific, the patients scored 21.4 AE 2.9 in the Necessity subscale and 13.6 AE 4.2 in the Concern subscale. The Necessity-concern differential was 7.8 AE 5.3, with 92.6% having a positive score and 3.7% scoring zero ( Table 2 ). The general population answered only the BMQ General. They believed medicines to be more harmful, yet less overprescribed compared to the dialysis patients ( Figure 2) .
When comparing men and women, and HD and PD patients, no differences were found in any of the subscales. In correlation analyses, the Harm subscale was associated with level of education (rho = −0.226, P < 0.001), depression (rho = 0.173, P = 0.01), comorbidity (rho = 0.153, P = 0.012), and age (rho = 0.253, P < 0.001), while the Overuse subscale was associated with level of education (rho = −0.176, P = 0.005), depression (rho = 0.195, P = 0.003), and age (rho = 0.113, P < 0.001). The Necessity subscale correlated with level of education (rho = 0.127, P = 0.044) and age (rho = −0.152, P = 0.012), and the Concern subscale correlated with education (rho = −0.143, P = 0.024) and depression (rho = 0.396, P < 0.001). None of the BMQ subscales were correlated with BMI or daily pill burden. The results of the multivariate model assessing associations between the BMQ subscales and the selected independent variables are given in Table 3 .
Beliefs about medicine in the transition from dialysis to transplantation A total of 142 patients were transplanted during the 55 AE 6.5 months of follow-up, of which 110 could be included in the follow-up part of the study. RTX patients (n = 96) had filled out the BMQ both while in dialysis and after transplantation, three of which had missing data in one of the subscales. After transplantation, the RTX patients reported they believed medicines to be less harmful than while in dialysis and less overprescribed. They also believed more in the necessity of their medicines, but they were just as concerned as before. These findings are presented in Figure 3 . The Necessity-concern differential increased markedly after transplantation (9.1 AE 5.7 vs. 11.5 AE 5.6, P < 0.001) and the proportion of patients reporting a positive score increased from 93.5% to 97.8%. Only one patient reported a negative score and one scored zero.
DISCUSSION
Only a few studies have investigated how medications are perceived by patients, and to the best of our knowledge, this is the first study to assess beliefs about medicines in Scandinavian dialysis patients. We found that patients in dialysis believed medications to be less harmful, yet more overprescribed compared to the general population. Furthermore, after RTX, the patients had strengthened their beliefs in the necessity of the medications and believed them to be less harmful and overprescribed.
Over 1/3rd of the dialysis patients were concerned about taking medications as they scored above midscale on the Concern subscale. This is in accordance with previous studies assessing concern of use of medication in different populations with chronic diseases 14, [19] [20] [21] [22] (ESRD, diabetes, hypertension, and chronic cardiovascular disease). Addressing the reasoning behind these concerns may be important, to identify if it is based on incorrect assumptions, for example, inaccurate beliefs about the long-term effects of their medication. 23 In the present study, around 20% of the general population scored above midscale in the Harm subscale, which is consistent with other studies. 24 However, the observation that the general population believed medicines to be more harmful than the patient group is rather surprising. Several aspects might explain this result, such as the experience of symptom relief among the dialysis patients. These patients experience a vast range of different and disturbing symptoms 25, 26 that may be relieved by medicines. Patient education has previously been shown to have a beneficial effect with regard to the use of medication. 27 Depressive symptoms are frequent in any dialysis population. 28, 29 Depressive symptoms were associated with high scores in the subscales Harm, Overuse, and Concern. Some studies have found that depression may be linked to a low Necessity-concern differential, meaning that the patients' concerns about their medications surpass the expected necessity of them. 6, 30 The same studies 6, 30 showed that this may be an important barrier to adherence, while others have not found similar associations. 31, 32 Depression is a known predictor of both graft loss and mortality in ESRD patients, 33, 34 but the cause of these associations are not known. However, a plausible part of the explanation may be that patients with more depressive symptoms are less adherent to medications than patients without these symptoms.
The level of education was associated with the beliefs about medicines. Other studies have not been able to find this association. 23, 35 Patients with higher education reported their medication to be less harmful and overused, and they had less concerns and scored higher on the necessity of their medication. Younger patients were more confident with the use of their medications than older patients. This may suggest that elderly patients with less education need more information about prescribed medication to enhance adherence. RTX patients reported higher necessity of medicines than while in dialysis. The Necessity-concern differential, which is found to be correlated with adherence, 6, 36 increased markedly. One reason for this increase may be that the patients are thoroughly informed and trained about the use and necessity of immunosuppressants after RTX. Another reason may be that the risk of having to return to dialysis is encouragement enough to stay adherent.
The BMQ scores after RTX are similar to the ones reported in a Swedish study exploring beliefs about medicine in patients after RTX, 32 with the exception of the patients in our study reporting a higher Necessity score. The Swedish study found a self-reported adherence of 46%. In a meta-analysis investigating risk factors for nonadherence among solid organ transplant recipients, RTX recipients had the highest rates of nonadherence. 11 The authors suggest that this may be a result of RTX recipients having the option of returning to dialysis. Targeted patient education about clinical consequences of graft loss may strengthen RTX patients' adherence.
The longitudinal design and the fairly large sample size, with almost one third of the dialysis population in Norway at the time of inclusion, strengthen the present study. Furthermore, a high percentage of the patients participated in the follow-up study and none of the patients were lost to follow-up. The transplantation recruitment procedure was similar in all dialysis units, and transplantations took place in one center. This study is also one of few that investigate beliefs among Scandinavian dialysis and transplanted patients and compare the results to a representative sample of the general population. There are some limitations in this study that should be taken into account when interpreting the findings. Very few patients were non-Caucasian, as patients with inadequate Norwegian language skills were not included. The time in dialysis before RTX was fairly short. These aspects may limit the generalizability of our results. The inclusion criteria may have led to selection bias toward healthier patients as patients with cognitive dysfunction, drug abuse, or hospitalized patients were excluded. The dialysis patients had to answer the questionnaire 30 minutes into the dialysis session and finish before the end of dialysis. This might have contributed to inadequate attention when completing the questionnaire. 
